Obalon Therptcs (NASDAQ: OBLN) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its competitors? We will compare Obalon Therptcs to similar businesses based on the strength of its profitability, institutional ownership, valuation, dividends, analyst recommendations, risk and earnings.


This table compares Obalon Therptcs and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Obalon Therptcs -459.54% -59.77% -47.02%
Obalon Therptcs Competitors -101.23% -92.70% -30.32%

Earnings & Valuation

This table compares Obalon Therptcs and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Obalon Therptcs $3.39 million -$20.46 million -4.13
Obalon Therptcs Competitors $1.67 billion $207.58 million 84.47

Obalon Therptcs’ competitors have higher revenue and earnings than Obalon Therptcs. Obalon Therptcs is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Obalon Therptcs and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Obalon Therptcs 1 0 2 0 2.33
Obalon Therptcs Competitors 110 728 1026 10 2.50

Obalon Therptcs presently has a consensus target price of $12.00, suggesting a potential upside of 46.16%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.31%. Given Obalon Therptcs’ higher probable upside, research analysts clearly believe Obalon Therptcs is more favorable than its competitors.

Volatility and Risk

Obalon Therptcs has a beta of -4.31, meaning that its stock price is 531% less volatile than the S&P 500. Comparatively, Obalon Therptcs’ competitors have a beta of 0.47, meaning that their average stock price is 53% less volatile than the S&P 500.

Insider and Institutional Ownership

44.1% of Obalon Therptcs shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 16.4% of Obalon Therptcs shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


Obalon Therptcs competitors beat Obalon Therptcs on 8 of the 12 factors compared.

About Obalon Therptcs

Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

Receive News & Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related companies with MarketBeat.com's FREE daily email newsletter.